Khanh T Do

11PUBLICATIONS
92CO-AUTHORS
Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

|Jul 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors.

Geraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar

|Jun 14, 2025
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.

Ryan J Sullivan, Oladapo O Yeku, Deanna Teoh

|Oct 25, 2024
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.

Gregory M Cote, Bose S Kochupurakkal, Khanh Do

|Mar 08, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.

Ryan B Corcoran, Khanh T Do, Jeong E Kim

|Oct 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.

James Nguyen, Naoko Takebe, Shivaani Kummar

Pageof 2

Frequent Collaborators

3 joint publications

Geoffrey I Shapiro

3 joint publications

Naoko Takebe

3 joint publications

Shivaani Kummar

3 joint publications

Geraldine O'Sullivan Coyne